Interviews
News Flash
Saltigo inaugurates APIs & intermediates plant in Leverkusen
14 Feb '08
2 min read
Saltigo GmbH, a wholly owned subsidiary of the LANXESS specialty chemicals group, has now officially inaugurated a state-of-the-art multi-purpose unit for the production of active pharmaceutical ingredients and intermediates.
This CGMP facility (CGMP = Current Good Manufacturing Practice) was built in 2006/07 based on an existing plant complex and cost around EUR 10 million.
In total, the unit's four production modules can produce more than 200 tons of active pharmaceutical ingredients (APIs) and registered intermediates a year.
Saltigo's Managing Director, Wolfgang Schmitz, explained at a press conference: "We will continue our process of investment to further enhance Saltigo's performance and competitiveness, and continuously adapt our facilities to the market requirements. In all, we will spend EUR 50 million or so on this up to the end of 2009."
State of North Rhine-Westphalia has specific advantages With production facilities in Leverkusen and Dormagen, Saltigo will continue to back North Rhine-Westphalia as a location. The vast majority of the company's 1,400 or so employees are based there.
"We have been bold in making the right preparations to successfully catch up with our competitors in the profitability stakes.
In the about two years since Saltigo was established, we have thus proved that our technology and innovation-driven business can be run successfully and profitably at sites with high wage costs," saidSchmitz.
He stressed the fact that, with well-trained and experienced employees, an excellent infrastructure and direct access to technical and scientific innovation, the sites had major competitive advantages that had made Saltigo an important and internationally respected company within a very short time.
Click here to view more:
This CGMP facility (CGMP = Current Good Manufacturing Practice) was built in 2006/07 based on an existing plant complex and cost around EUR 10 million.
In total, the unit's four production modules can produce more than 200 tons of active pharmaceutical ingredients (APIs) and registered intermediates a year.
Saltigo's Managing Director, Wolfgang Schmitz, explained at a press conference: "We will continue our process of investment to further enhance Saltigo's performance and competitiveness, and continuously adapt our facilities to the market requirements. In all, we will spend EUR 50 million or so on this up to the end of 2009."
State of North Rhine-Westphalia has specific advantages With production facilities in Leverkusen and Dormagen, Saltigo will continue to back North Rhine-Westphalia as a location. The vast majority of the company's 1,400 or so employees are based there.
"We have been bold in making the right preparations to successfully catch up with our competitors in the profitability stakes.
In the about two years since Saltigo was established, we have thus proved that our technology and innovation-driven business can be run successfully and profitably at sites with high wage costs," saidSchmitz.
He stressed the fact that, with well-trained and experienced employees, an excellent infrastructure and direct access to technical and scientific innovation, the sites had major competitive advantages that had made Saltigo an important and internationally respected company within a very short time.
Click here to view more:
LANXESS AG
Popular News
Leave your Comments
Editor’s Pick
Ritesh Dodhia
Dodhia Synthetics Limited
S. Chendhuran
SP Retail Ventures Limited
Esteemed Clients
-Ltd..jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Thermore (Far East) Ltd.")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Telangana State Industrial Infrastructure Corporation Limited (TSllC Ltd)")
.jpg?tr=w-120,h-60,c-at_max,cm-pad_resize,bg-ffffff "Taiwan Textile Federation (TTF)")
